Vagus nerve stimulation exerts cardioprotection against doxorubicin-induced cardiotoxicity through inhibition of programmed cell death pathways

被引:13
|
作者
Prathumsap, Nanthip [1 ,2 ,3 ]
Ongnok, Benjamin [1 ,2 ,3 ]
Khuanjing, Thawatchai [1 ,2 ,3 ]
Arinno, Apiwan [1 ,2 ,3 ]
Maneechote, Chayodom [1 ,3 ]
Apaijai, Nattayaporn [1 ,2 ,3 ]
Chunchai, Titikorn [1 ,3 ]
Arunsak, Busarin [1 ,3 ]
Kerdphoo, Sasiwan [1 ,3 ]
Janjek, Sornram [1 ,3 ]
Chattipakorn, Siriporn C. [1 ,3 ,4 ]
Chattipakorn, Nipon [1 ,2 ,3 ]
机构
[1] Chiang Mai Univ, Fac Med, Cardiac Electrophysiol Res & Training Ctr, Chiang Mai 50200, Thailand
[2] Chiang Mai Univ, Fac Med, Dept Physiol, Cardiac Electrophysiol Unit, Chiang Mai 50200, Thailand
[3] Chiang Mai Univ, Ctr Excellence Cardiac Electrophysiol, Chiang Mai 50200, Thailand
[4] Chiang Mai Univ, Fac Dent, Dept Oral Biol & Diagnost Sci, Chiang Mai 50200, Thailand
关键词
Vagus nerve stimulation; Doxorubicin; Cardiotoxicity; Programmed cell death; HEART-FAILURE; MITOCHONDRIAL DYNAMICS; H9C2; CELLS; APOPTOSIS; MECHANISMS; AUTOPHAGY; IMPROVES; THYMOQUINONE; PATHOGENESIS; NECROPTOSIS;
D O I
10.1007/s00018-022-04678-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The aberration of programmed cell death including cell death associated with autophagy/mitophagy, apoptosis, necroptosis, pyroptosis, and ferroptosis can be observed in the development and progression of doxorubicin-induced cardiotoxicity (DIC). Vagus nerve stimulation (VNS) has been shown to exert cardioprotection against cardiomyocyte death through the release of the neurotransmitter acetylcholine (ACh) under a variety of pathological conditions. However, the roles of VNS and its underlying mechanisms against DIC have never been investigated. Forty adults male Wistar rats were divided into 5 experimental groups: (i) control without VNS (CSham) group, (ii) doxorubicin (3 mg/kg/day, i.p.) without VNS (DSham) group, (iii) doxorubicin + VNS (DVNS) group, (iv) doxorubicin + VNS + mAChR antagonist (atropine; 1 mg/kg/day, ip, DVNS + Atro) group, and (v) doxorubicin + VNS + nAChR antagonist (mecamylamine; 7.5 mg/kg/day, ip, DVNS + Mec) group. Our results showed that doxorubicin insult led to left ventricular (LV) dysfunction through impaired cardiac autonomic balance, decreased mitochondrial function, imbalanced mitochondrial dynamics, and exacerbated cardiomyocyte death including autophagy/mitophagy, apoptosis, necroptosis, pyroptosis, and ferroptosis. However, VNS treatment improved cardiac mitochondrial and autonomic functions, and suppressed excessive autophagy, apoptosis, necroptosis, pyroptosis, and ferroptosis, leading to improved LV function. Consistent with this, ACh effectively improved cell viability and suppressed cell cytotoxicity in doxorubicin-treated H9c2 cells. In contrast, either inhibitors of muscarinic (mAChR) or nicotinic acetylcholine receptor (nAChR) completely abrogated the favorable effects mediated by VNS and acetylcholine. These findings suggest that VNS exerts cardioprotective effects against doxorubicin-induced cardiomyocyte death via activation of both mAChR and nAChR.
引用
收藏
页数:22
相关论文
共 50 条
  • [1] Vagus nerve stimulation exerts cardioprotection against doxorubicin-induced cardiotoxicity through inhibition of programmed cell death pathways
    Nanthip Prathumsap
    Benjamin Ongnok
    Thawatchai Khuanjing
    Apiwan Arinno
    Chayodom Maneechote
    Nattayaporn Apaijai
    Titikorn Chunchai
    Busarin Arunsak
    Sasiwan Kerdphoo
    Sornram Janjek
    Siriporn C. Chattipakorn
    Nipon Chattipakorn
    Cellular and Molecular Life Sciences, 2023, 80
  • [2] Vagus Nerve Stimulation Exerts Cardioprotection Against Doxorubicin-Induced Cardiotoxicity Through Improving Cardiac Mitochondrial Function and Autonomic Tone
    Prathumsap, Nanthip
    Ongnok, Benjamin
    Khuanjing, Thawatchai
    Arinno, Apiwan
    Maneechote, Chayodom
    Apaijai, Nattayaporn
    Chunchai, Titikorn
    Arunsak, Busarin
    Kerdphoo, Sasiwan
    Shinlapawittayatorn, Krekwit
    Chattipakorn, Siriporn
    Chattipakorn, Nipon
    CIRCULATION, 2021, 144
  • [3] Regulated cell death pathways in doxorubicin-induced cardiotoxicity
    Effimia Christidi
    Liam R. Brunham
    Cell Death & Disease, 12
  • [4] Regulated cell death pathways in doxorubicin-induced cardiotoxicity
    Christidi, Effimia
    Brunham, Liam R.
    CELL DEATH & DISEASE, 2021, 12 (04)
  • [5] New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity
    El-Demerdash, E
    Ali, AA
    Sayed-Ahmed, MM
    Osman, AMM
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (05) : 411 - 416
  • [6] New aspects in probucol cardioprotection against doxorubicin-induced cardiotoxicity
    Ebtehal El-Demerdash
    Azza A. Ali
    Mohamed M. Sayed-Ahmed
    Abdel-Moneim M. Osman
    Cancer Chemotherapy and Pharmacology, 2003, 52 : 411 - 416
  • [7] The mechanism and therapeutic strategies in doxorubicin-induced cardiotoxicity: Role of programmed cell death
    Li, Yanzhao
    Yan, Jing
    Yang, Pingzhen
    CELL STRESS & CHAPERONES, 2024, 29 (05): : 666 - 680
  • [8] Ranolazine exerted cardioprotection against doxorubicin-induced cardiotoxicity through inhibiting excessive autophagy in rats
    Arinno, A.
    Maneechote, C.
    Khuanjing, T.
    Chunchai, T.
    Prathumsap, N.
    Ongnok, B.
    Arunsak, B.
    Jaiwongkam, T.
    Kerdphoo, S.
    Shinlapawittayatorn, K.
    Chattipakorn, S. C.
    Chattipakorn, N.
    EUROPEAN HEART JOURNAL, 2021, 42 : 3012 - 3012
  • [9] Acetylcholinesterase inhibition protects against trastuzumab-induced cardiotoxicity through reducing multiple programmed cell death pathways
    Khuanjing, Thawatchai
    Maneechote, Chayodom
    Ongnok, Benjamin
    Prathumsap, Nanthip
    Arinno, Apiwan
    Chunchai, Titikorn
    Arunsak, Busarin
    Chattipakorn, Siriporn C.
    Chattipakorn, Nipon
    MOLECULAR MEDICINE, 2023, 29 (01)
  • [10] Acetylcholinesterase inhibition protects against trastuzumab-induced cardiotoxicity through reducing multiple programmed cell death pathways
    Thawatchai Khuanjing
    Chayodom Maneechote
    Benjamin Ongnok
    Nanthip Prathumsap
    Apiwan Arinno
    Titikorn Chunchai
    Busarin Arunsak
    Siriporn C. Chattipakorn
    Nipon Chattipakorn
    Molecular Medicine, 29